Efficacy of twice-daily amoxycillin/clavulanate in lower respiratory tract infections.
In this double-blind, double-dummy study, 324 patients with clinical evidence of community-acquired pneumonia (CAP) or an acute exacerbation of chronic bronchitis were randomly assigned to receive 10 days' treatment with either amoxycillin/clavulanate 875/125 mg twice daily or amoxycillin/clavulanate 500/125 mg three times daily. At the end of therapy, clinical success rates were 92.4% for the twice daily regimen and 94.2% for the three times daily regimen. There was no statistically significant difference between treatments (p = 0.647) and the 95% confidence interval around the treatment difference indicated that the two treatments were equivalent. Treatment equivalence was also confirmed at follow-up, four weeks after the end of treatment. Both regimens were well tolerated. In conclusion, amoxycillin/clavulanate 875/125 mg twice daily is as effective as amoxycillin/clavulanate 500/125 mg three times daily for the treatment of community-acquired lower respiratory tract infections and could improve patient compliance.
Balgos
A A
AA
Department of Medicine, Philippine General Hospital, Manila, Philippines.
Rodriguez-Gomez
G
G
Nasnas
R
R
Mahasur
A A
AA
Margono
B P
BP
Tinoco-Favila
J C
JC
Sansores-Martinez
R H
RH
Hassan
M
M
Beppo
O
O
Wongsa
A
A
Cukier
A
A
Vargas
F
F
D000293:Adolescent; D000328:Adult; D000368:Aged; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000008:administration & dosage* / Q000009:adverse effects; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D017714:Community-Acquired Infections / Q000188:drug therapy; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy*; D016896:Treatment Outcome
D019980:Amoxicillin-Potassium Clavulanate Combination